Lumida
/UPB
⌘K
Upstream Bio Inc

Upstream Bio Inc

UPB
$7.01USD-3.04%-0.22 today

MARKET CAP

381.5M

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $7

52W RANGE

$6
$34

AI Summary

Stalk
Sell NowMedium

UPB remains entrenched in a Stage 4 decline with price trading below its key moving averages. Medium-term bias is bearish, reinforced by a series of lower highs and lower lows and dynamic resistance at the 9/21 EMAs. Despite extreme oversold readings, recent rallies into EMAs have been rejected, supporting a Sell Now posture. A break and hold above the 21 EMA would invalidate this bearish timing edge.

  • TipRanks 'Strong Buy' PT $42.33 implies ~462% upside from $7.51
  • 13F ownership high signals institutional confidence in UPB
  • Earnings yield –3.95% and negative profitability raise distress
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 16, 2026SellUPBAllison AmbroseGeneral Counsel477$6.10$381.5M-79.19%+19.83%$2.9K-2.89%Sell Now
Jun 16, 2026SellUPBAdam HoughtonChief Business Officer700$6.10$381.5M-79.19%+19.83%$4.3K-2.88%Sell Now
Jun 16, 2026SellUPBMichael GrayCFO and COO853$6.10$381.5M-79.19%+19.83%$5.2K-2.88%Sell Now
Jun 16, 2026SellUPBAaron DeykinChief Medical Officer895$6.10$381.5M-79.19%+19.83%$5.5K-2.63%Sell Now
Jun 16, 2026SellUPBEverett Rand SutherlandChief Executive Officer2,095$6.10$381.5M-79.19%+19.83%$12.8K-2.87%Sell Now
Mar 16, 2026SellUPBAllison AmbroseGeneral Counsel475$9.29$381.5M-79.19%+19.83%$4.4K-2.79%Sell Now
Mar 16, 2026SellUPBAdam HoughtonChief Business Officer699$9.29$381.5M-79.19%+19.83%$6.5K-2.80%Sell Now
Mar 16, 2026SellUPBMichael GrayCFO and COO852$9.29$381.5M-79.19%+19.83%$7.9K-2.79%Sell Now
Mar 16, 2026SellUPBAaron DeykinChief Medical Officer894$9.29$381.5M-79.19%+19.83%$8.3K-2.66%Sell Now
Mar 16, 2026SellUPBEverett Rand SutherlandChief Executive Officer2,093$9.29$381.5M-79.19%+19.83%$19.4K-2.79%Sell Now